The introduction of House Speaker Nancy Pelosi’s government drug pricing bill set in motion much of the political maneuvering that lobbyists had been trying to predict, but the outcome of drug pricing legislation is still far off. This week, Congress will provide more insights into what might transpire as the House Energy & Commerce health subcommittee holds a legislative hearing, but markups in the three House committees of jurisdiction aren’t expected until after the October recess . First, here are...